344413-83-8

Usage

Uses

Used in Pharmaceutical Industry:
(2R)-3-amino-2-fluoropropan-1-ol is used as a key intermediate in the synthesis of various drugs and pharmaceuticals. Its unique structure allows for the development of new therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Industry:
(2R)-3-amino-2-fluoropropan-1-ol is used as a building block in the production of agrochemicals, such as pesticides and herbicides. Its unique properties can contribute to the development of more effective and environmentally friendly agrochemicals.
Used in Medicinal Chemistry Research:
(2R)-3-amino-2-fluoropropan-1-ol is used as a valuable chemical in medicinal chemistry research for the exploration of new drug candidates and the optimization of existing ones. Its unique structural features can be leveraged to design and synthesize novel compounds with potential therapeutic applications.
Used in the Development of Novel Materials:
The presence of the fluorine atom in (2R)-3-amino-2-fluoropropan-1-ol gives it unique properties that can be utilized in the development of novel materials and compounds. Its application in this field can lead to the creation of new materials with improved properties for various industrial applications.

Downstream Products

• 344413-84-9 tert-butyl [2-fluoro-3-hydroxypropyl]carbamate 

Relevant academic research and scientific papers

1-HETEROARYL-INDOLINE-4-CARBOXAMIDES AS MODULATORS OF GPR52 USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (la) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a GPR52-mediated disorder (e.g., Huntington's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), or Tourette's syndrome); an extrapyramidal or movement disorder; a motor disorder; a hyperkinetic movement disorder; a psychotic disorder; catatonia; a mood disorder; a depressive disorder; an anxiety disorder; obsessive-compulsive disorder (OCD); an autism spectrum disorder; a prolactin-related disorder (e.g., hyperprolactinemia); a neurocognitive disorder; a trauma- or stressor-related disorder (e.g., posttraumatic stress disorder (PTSD)); a disruptive, impulse-control, or conduct disorder; a sleep-wake disorder; a substance-related disorder; an addictive disorder; a behavioral disorder; hypofrontality; an abnormality in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway; decreased activity in the striatum; cortical dysfunction; neurocognitive dysfunction; and conditions related thereto.

SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS

Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof

Synthesis and pharmacological evaluation of novel γ-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors

We have previously demonstrated that the prototypical GABAB receptor agonist baclofen inhibits transient lower esophageal sphincter relaxations (TLESRs), the most important mechanism for gastroesophageal reflux. Thus, GABAB agonists could be exploited for the treatment of gastroesophageal reflux disease. However, baclofen, which is used as an antispastic agent, and other previously known GABAB agonists can produce CNS side effects such as sedation, dizziness, nausea, and vomiting at higher doses. We now report the discovery of atypical GABAB agonists devoid of classical GABAB agonist related CNS side effects at therapeutic doses and the optimization of this type of compound for inhibition of TLESRs, which has resulted in a candidate drug (R)-7 (AZD3355) that is presently being evaluated in man.

Substituted imidazole compounds as KSP inhibitors

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds. The compounds of the invention have the following general formula: